22nd Century Group

22nd Century Group EBIT per Share

The EBIT per Share of 22nd Century Group (XXII) as of Nov 1, 2026 is -24.93 USD. In the previous year, EBIT per Share was -11,202.50 USD — a change of -99.78% (higher).

EBIT per Share

-24.93USD

YoY

-99.78%

Last updated:

EBIT per Share of 22nd Century Group is 2025 -24.93 USD. EBIT per Share of 22nd Century Group was 2024 -11,202.50 USD. It decreases by -99.78% higher compared to the previous year.

The 22nd Century Group EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2019
-2.81 USD
Jan 1, 2020
-2.07 USD
Jan 1, 2021
-2.62 USD
Jan 1, 2022
-2.54 USD
Jan 1, 2024
-11,202.50 USD
Jan 1, 2025
-24.93 USD
Jan 1, 2026 (e)
629.98 USD
Jan 1, 2027 (e)
0.00 USD
The 22nd Century Group EBIT per Share history
YEAREBIT per ShareYoY
est0.00USD-100.00%
est629.98USD-2,627.29%
-24.93USD-99.78%
-11,202.50USD+440,512.63%
-2.54USD-2.90%
-2.62USD+26.31%
-2.07USD-26.18%
-2.81USD-3.12%
-2.90USD+46.98%
-1.97USD-9.07%
-2.17USD-18.20%
-2.65USD-9.66%
-2.93USD-101.57%
186.91USD-138.95%
-479.90USD-20.43%
-603.14USD+2,762.12%
-21.07USD+53.76%
-13.71USD-35.65%
-21.30USD+175.03%
-7.74USD-75.18%
-31.20USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

22nd Century Group Stock analysis

What does 22nd Century Group do? 22nd Century Group, Inc. develops biotechnology solutions for tobacco and cannabis plants, focusing on genetic engineering to adjust nicotine levels in tobacco and cannabinoid levels in cannabis. The company creates products like RED SUN and MAGIC cigarettes, which it manufactures, markets, and distributes. It also produces SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA) and offers contract manufacturing for third-party branded tobacco products. The firm's revenue streams include sales of its branded cigarettes, research cigarette production, and contract manufacturing services. The company's primary customers are consumers of its RED SUN and MAGIC cigarette brands, research institutions like NIDA, and third-party tobacco brands seeking contract manufacturing. Its product lines target segments interested in reduced nicotine content for smoking cessation and research purposes. The X-22 smoking cessation aid, featuring very low nicotine (VLN) cigarettes, represents a key product in its portfolio aimed at helping users reduce nicotine dependency. 22nd Century Group's business model revolves around selling its proprietary tobacco products, providing research-grade cigarettes for scientific studies, and fulfilling manufacturing contracts for other brands. The company's focus on genetic engineering for nicotine reduction positions it within the market for less harmful tobacco alternatives, while its contract manufacturing services diversify its revenue sources beyond direct consumer sales. 22nd Century Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 22nd Century Group stock

EBIT per Share of 22nd Century Group is -24.93 USD in 2025.

EBIT per Share of 22nd Century Group changed from -11,202.50 USD to -24.93 USD, representing a -99.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share 22nd Century Group since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — 22nd Century Group

All Key Metrics — 22nd Century Group